Self-administration training Just like hundreds of Berinert patients, with the proper training you can infuse Berinert on your own or with help from a family member or other caregiver.

One-on-one training from a nurse or other healthcare professional can help you develop confidence to safely and effectively self-administer Berinert at the first sign of an HAE attack. Remember—never attempt to selfadminister Berinert unless you’ve been taught to do so by a healthcare professional.

Seek immediate medical attention if an HAE attack has progressed to a point where you will be unable to prepare or administer Berinert.

If you self-administer to treat a laryngeal attack, immediately seek medical attention afterward.

*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians.

Training materials

Berinert provides numerous self-administration training and practice materials to help patients become accustomed to the procedure. These materials are provided to the patient through a specialty-pharmacy training nurse. Speak with your doctor or BEN to arrange a training session.

Self-Administration Slide Show

Instructional Self-Administration Video

Contact B.E.N. for help in arranging self-administration training.

Let us take the hassle out of taking control of your HAE therapy. B.E.N. can assist you in starting or selfadministering your Berinert therapy.

continue to
Support Services

B.E.N. (Berinert Expert Network) is available to help with insurance and treatment questions and provide information about patient assistance programs.

Home Getting Started with Berinert Self-Administration Training
Expand

Important Safety Information

Berinert®, C1 Esterase Inhibitor (Human), is used in adults and children to treat swelling and/or painful attacks of hereditary angioedema (HAE) affecting the abdomen, face or throat. The safety and efficacy of Berinert in preventing HAE attacks have not been established.

Do not use Berinert if you have experienced life-threatening allergic reactions or severe hypersensitivity to the product. Inform your healthcare provider of all medications you are taking and of any medical conditions, especially any history of blood-clotting problems.

Blood clots have occurred in patients receiving Berinert. Tell your healthcare provider if you have a history of heart or blood vessel disease, stroke, or blood clots, or if you have thick blood, an indwelling catheter/access device in a vein, or have been immobile for some time. Certain medications, such as birth control pills, may also increase your risk of clotting problems.

Report to your physician or an emergency room any signs and symptoms of a blood clot, including pain and/or swelling or discoloration of an arm or leg, with warmth over affected area; unexplained shortness of breath; chest pain or discomfort that worsens on deep breathing; rapid pulse; and numbness or weakness on one side of the body.

In addition, report immediately any signs or symptoms of allergic reactions to Berinert, including hives, chest tightness, wheezing, difficulty breathing, turning blue, faintness, facial swelling and fast heartbeat.

If you have been trained to self-administer Berinert, immediately prepare the prescribed dose at the first symptoms of an attack. Seek immediate medical attention and do not begin to self-adminster if an HAE attack has progressed to a point where you will be unable to prepare or administer a dose of Berinert.

If you self-administer to treat a laryngeal attack, immediately seek medical attention afterward. If you self-administer for an abdominal attack, inform your physician so that other possible causes can be ruled out.

Call your doctor right away if swelling is not controlled after use of Berinert.

In clinical studies, the most serious adverse reaction reported in subjects who received Berinert was an increased severity of the pain associated with HAE. In the placebo-controlled clinical trial, the most common adverse reaction reported more often among subjects who received Berinert than those receiving placebo was dysgeusia (a bad taste in mouth). Tell your healthcare provider about any side effect that bothers you or does not go away.

Because Berinert is made from human blood, the risk that it may transmit infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

Please see full prescribing information for Berinert, including the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Collapse
CSL Behring
© 2017 CSL Behring. The product information presented on this site is intended for US residents only. BRN/03-13-0059(1)d